AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

AstraZeneca (NASDAQ:AZN) said on Tuesday it will discontinue its late stage trial testing Truqap combination in patients with ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

AstraZeneca delivered a strong performance in the first quarter of 2025, it announced on Tuesday, with total revenue rising ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to meet its endpoints. The CAPItello-280 study (NCT05348577 ...

AstraZeneca (NASDAQ:AZN) said on Tuesday it will discontinue a late-stage trial testing a drug combination involving its FDA-approved therapy Truqap in patients with metastatic castration ...